Matches in SemOpenAlex for { <https://semopenalex.org/work/W2343546819> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2343546819 abstract "Introduction: Dofetilide is a class III anti-arrhythmic agent approved for achieving and maintaining sinus rhythm in patients with symptomatic atrial fibrillation or flutter (AF). Due to a risk of QT prolongation and ventricular tachycardia (VT) patients initiated on Dofetilide need to be hospitalized for at least 3 days to closely monitor ECG. In large clinical trials 1.8-2.5% of the patients had to discontinue Dofetilide due to QT prolongation. We aimed to evaluate the frequency and correlates of discontinuation of Dofetilide due to QT prolongation (QTc >500 msec) or VT in a real-world, inpatient setting. Methods: We included 100 consecutive patients, hospitalized for Dofetilide initiation at the Minneapolis VA Medical Center from 2011 to 2014. Data was collected retrospectively from electronic medical records. Results: The mean age was 63.8 ± 9.1 years. The indication for Dofetilide was AF (88%) and VT (12%). Dofetilide had to be discontinued in 21% of the patients due to QTc prolongation (17%) or VT (2%) or lack of efficacy (2%). One patient died in the hospital. The mean QTc in patients in whom Dofetilide had to be discontinued was 512±53 msec. In 29% of the cases Dofetilide cardioverted patients to sinus rhythm. Patients who had to discontinue Dofetilide were less likely to have coronary heart disease (CHD) than those who were discharged on Dofetilide (14% vs. 44%, respectively; p= 0.012) (Table). The average number of doses received by patients before discharge was 5.5±0.9 in patients who were discharged on Dofetilde vs. 3.2±1.5 in whom Dofetilide was discontinued because of QTc prolongation (55% discontinued after 2 nd dose). Concomitant QTc prolonging drugs were used in 29% of patients who had to discontinue Dofetilide vs. 24% of those who were discharged on Dofetilide (p=0.78) (Table). Conclusion: The incidence of Dofetilide discontinuation due to high-risk ECG features in the real world setting is remarkably higher than that reported in prior clinical trials." @default.
- W2343546819 created "2016-06-24" @default.
- W2343546819 creator A5060506670 @default.
- W2343546819 creator A5071058483 @default.
- W2343546819 creator A5081475141 @default.
- W2343546819 date "2015-11-10" @default.
- W2343546819 modified "2023-09-24" @default.
- W2343546819 title "Abstract 14763: Discontinuation of Dofetilide or Qt Prolongation is Much More Common in Real-world Setting Than Reported in Clinical Trials" @default.
- W2343546819 hasPublicationYear "2015" @default.
- W2343546819 type Work @default.
- W2343546819 sameAs 2343546819 @default.
- W2343546819 citedByCount "0" @default.
- W2343546819 crossrefType "journal-article" @default.
- W2343546819 hasAuthorship W2343546819A5060506670 @default.
- W2343546819 hasAuthorship W2343546819A5071058483 @default.
- W2343546819 hasAuthorship W2343546819A5081475141 @default.
- W2343546819 hasConcept C118441451 @default.
- W2343546819 hasConcept C126322002 @default.
- W2343546819 hasConcept C164705383 @default.
- W2343546819 hasConcept C2775914520 @default.
- W2343546819 hasConcept C2776331378 @default.
- W2343546819 hasConcept C2777796741 @default.
- W2343546819 hasConcept C2778292772 @default.
- W2343546819 hasConcept C2778715236 @default.
- W2343546819 hasConcept C2779161974 @default.
- W2343546819 hasConcept C2780486423 @default.
- W2343546819 hasConcept C42219234 @default.
- W2343546819 hasConcept C71924100 @default.
- W2343546819 hasConceptScore W2343546819C118441451 @default.
- W2343546819 hasConceptScore W2343546819C126322002 @default.
- W2343546819 hasConceptScore W2343546819C164705383 @default.
- W2343546819 hasConceptScore W2343546819C2775914520 @default.
- W2343546819 hasConceptScore W2343546819C2776331378 @default.
- W2343546819 hasConceptScore W2343546819C2777796741 @default.
- W2343546819 hasConceptScore W2343546819C2778292772 @default.
- W2343546819 hasConceptScore W2343546819C2778715236 @default.
- W2343546819 hasConceptScore W2343546819C2779161974 @default.
- W2343546819 hasConceptScore W2343546819C2780486423 @default.
- W2343546819 hasConceptScore W2343546819C42219234 @default.
- W2343546819 hasConceptScore W2343546819C71924100 @default.
- W2343546819 hasLocation W23435468191 @default.
- W2343546819 hasOpenAccess W2343546819 @default.
- W2343546819 hasPrimaryLocation W23435468191 @default.
- W2343546819 hasRelatedWork W1556120217 @default.
- W2343546819 hasRelatedWork W2032268067 @default.
- W2343546819 hasRelatedWork W2074415660 @default.
- W2343546819 hasRelatedWork W2227804096 @default.
- W2343546819 hasRelatedWork W2334476781 @default.
- W2343546819 hasRelatedWork W2504295490 @default.
- W2343546819 hasRelatedWork W2623399953 @default.
- W2343546819 hasRelatedWork W2761632931 @default.
- W2343546819 hasRelatedWork W2886460305 @default.
- W2343546819 hasRelatedWork W2889963881 @default.
- W2343546819 hasRelatedWork W2896942647 @default.
- W2343546819 hasRelatedWork W2967961342 @default.
- W2343546819 hasRelatedWork W3005551797 @default.
- W2343546819 hasRelatedWork W3037230572 @default.
- W2343546819 hasRelatedWork W3089081925 @default.
- W2343546819 hasRelatedWork W3093512431 @default.
- W2343546819 hasRelatedWork W3116222882 @default.
- W2343546819 hasRelatedWork W3120690662 @default.
- W2343546819 hasRelatedWork W3124451930 @default.
- W2343546819 hasRelatedWork W3131959791 @default.
- W2343546819 hasVolume "132" @default.
- W2343546819 isParatext "false" @default.
- W2343546819 isRetracted "false" @default.
- W2343546819 magId "2343546819" @default.
- W2343546819 workType "article" @default.